News Sankyo Co., Ltd.

Equities

Market Closed - Japan Exchange Other stock markets 11:30:00 26/04/2024 am IST			5-day change	1st Jan Change
1,664 ^JPY	+1.87%		+1.93%	+1.15%

25/04	AstraZeneca upbeat as cancer drugs underpin sales growth	AN
08/04	AstraZeneca hails neurological data for Ultomiris, Soliris	AN

AstraZeneca upbeat as cancer drugs underpin sales growth	25/04	AN
AstraZeneca hails neurological data for Ultomiris, Soliris	08/04	AN
AstraZeneca's, Daiichi's Enhertu receives US FDA approval	08/04	AN
AstraZeneca, Daiichi make US progress with licence approvals	03/04	AN
AstraZeneca and Daiichi make US progress with latest licence approvals	02/04	AN
Final dividend	28/03	FA
Sankyo Exhausts Buyback Program After Repurchasing 50 Million Shares for 68.77 Billion Yen	26/03	MT
Tranche Update on Sankyo Co., Ltd.'s Equity Buyback Plan announced on November 7, 2023.	25/03	CI
Sankyo Co., Ltd.'s Equity Buyback announced on November 7, 2023, has closed with 50,000,000 shares, representing 19.32% for ¥68,767.93 million.	22/03	CI
AstraZeneca's breast cancer treatment blocked for NHS use in England	05/03	AN
AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment	04/03	AN
Split: 5 of 1	28/02	FA
Nikkei extends record rally on pharma boost	26/02	RE
Nikkei hits record high as index heavyweights advance	26/02	RE
AstraZeneca completes USD1.1 billion acquisition of Icosavax	19/02	AN
AstraZeneca celebrates Tagrisso approval and new data	19/02	AN
Sankyo Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Grow	08/02	MT
Sankyo Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023	07/02	CI
SANKYO Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	07/02	CI
SANKYO Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	07/02	CI

No results for this search